Autolus Therapeutics (NASDAQ:AUTL) Announces Quarterly Earnings Results

Autolus Therapeutics (NASDAQ:AUTL) announced its quarterly earnings data on Thursday. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02, Zacks reports. The firm had revenue of $26.22 million during the quarter, compared to the consensus estimate of $26.27 million. Autolus Therapeutics had a negative return on equity of 99.05% and a negative net margin of 381.40%.

Here are the key takeaways from Autolus Therapeutics’ conference call:

• Q1 revenue came in at $26.2 million, up sharply from $9.0 million a year ago, and management reiterated full-year 2026 revenue guidance of $120 million to $135 million.
• The company reported its first positive gross margin for AUCATZYL in the quarter, supported by higher volume and manufacturing/operational improvements, with margins expected to keep improving through 2026.
• Autolus said U.S. and U.K. launch momentum is building, with 73 U.S. centers active and more than 10 centers already live in the U.K.; management expects U.S. centers to exceed 80 by year-end.
• The company’s real-world data continue to support obe-cel’s profile, citing no high-grade CRS, 3% high-grade ICANS, and more than 90% overall response rate, while noting patient use is expanding into older and more complex populations.
• Management highlighted a broad pipeline for obe-cel, including pediatric ALL, lupus, lupus nephritis, progressive MS, and AL amyloidosis, with several data readouts expected in late 2026 through 2028.

Autolus Therapeutics Price Performance

Shares of Autolus Therapeutics stock traded down $0.12 during trading on Thursday, hitting $1.59. 2,996,422 shares of the company’s stock traded hands, compared to its average volume of 1,748,355. Autolus Therapeutics has a 1 year low of $1.18 and a 1 year high of $2.70. The stock has a market capitalization of $423.17 million, a P/E ratio of -1.47 and a beta of 1.93. The business has a 50-day simple moving average of $1.49 and a 200-day simple moving average of $1.51.

Analysts Set New Price Targets

A number of brokerages recently commented on AUTL. Mizuho decreased their target price on Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, March 31st. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Thursday, April 9th. Zacks Research raised Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. Weiss Ratings raised Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 29th. Finally, Jefferies Financial Group raised Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.75.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AUTL. Marex Group plc bought a new position in Autolus Therapeutics in the second quarter valued at about $28,000. SmartHarvest Portfolios LLC bought a new position in Autolus Therapeutics in the fourth quarter valued at about $43,000. Caitong International Asset Management Co. Ltd bought a new position in Autolus Therapeutics in the third quarter valued at about $46,000. Invesco Ltd. lifted its holdings in Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after acquiring an additional 11,381 shares during the period. Finally, Federation des caisses Desjardins du Quebec bought a new position in Autolus Therapeutics in the fourth quarter valued at about $62,000. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.